Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kristen Bano"'
Autor:
Siegfried Janz, Brian Van Ness, Joseph B. Bolen, Mark Manfredi, Erik Kupperman, Allison J. Berger, Vishala T. Neppalli, Mary Carsillo, Paul Hales, Ping Li, Olga Tayber, Zhi Li, Michael Pickard, Ray Liu, Matthew D. Silva, Ozlem Subakan, Daniel P. Bradley, Jennifer Terkelsen, Kristen Bano, Jill Donelan, Bret Bannerman, Michael Fitzgerald, Edmund C. Lee
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bf51cd992431bfa10c2e6773dbd8053
https://doi.org/10.1158/1078-0432.c.6520107
https://doi.org/10.1158/1078-0432.c.6520107
Autor:
Siegfried Janz, Brian Van Ness, Joseph B. Bolen, Mark Manfredi, Erik Kupperman, Allison J. Berger, Vishala T. Neppalli, Mary Carsillo, Paul Hales, Ping Li, Olga Tayber, Zhi Li, Michael Pickard, Ray Liu, Matthew D. Silva, Ozlem Subakan, Daniel P. Bradley, Jennifer Terkelsen, Kristen Bano, Jill Donelan, Bret Bannerman, Michael Fitzgerald, Edmund C. Lee
PDF file - 108K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24fd400a1ca08e8405e5d218dd1e0d4b
https://doi.org/10.1158/1078-0432.22444227.v1
https://doi.org/10.1158/1078-0432.22444227.v1
Autor:
Olga Tayber, Erik Kupperman, Zhi Li, Joseph B. Bolen, Ping Li, Kristen Bano, Jennifer Terkelsen, Allison Berger, Brian G Van Ness, Michael D. Pickard, Matthew D. Silva, Mary Carsillo, Paul Hales, Michael Fitzgerald, Siegfried Janz, Ozlem Subakan, Daniel P. Bradley, Mark Manfredi, Edmund Lee, Vishala T. Neppalli, Bret Bannerman, Jill Donelan, Raymond W. Liu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23)
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bort
Autor:
Bret Bannerman, Mark Manfredi, Kristen Bano, Yu Yang, Brad Stringer, Steve Blakemore, Jill Donelan, Nibedita Chattopadhyay, Allison Berger
Publikováno v:
Cancer Research. 71:2828-2828
The successful development of VELCADE® (bortezomib) for multiple myeloma and previously treated mantle cell lymphoma has validated the proteasome as a therapeutic target for hematological malignancies. The investigational drug MLN9708 is a modified
Autor:
Jill Donelan, David I. Lichter, Paul Hales, Erik Koenig, Kristen Bano, Laura Faron-Yowe, Bradley Stringer, Hadi Danaee, Bret Bannerman, Kristin E. Burke, Trisha Babcock, Erik Kupperman
Publikováno v:
Blood. 114:3724-3724
Abstract 3724 Poster Board III-660 Lymphomas account for about 5% of all cases of cancer in the US. In 2009, it is estimated that 74490 Americans will be diagnosed with lymphoma, which includes approximately 8510 new cases of Hodgkin's lymphoma and 6